ライフサイエンスコーパス: Oct-6

1 11 participants were recruited between Oct 6, 2008, and Dec 4, 2009.

2 d, placebo-controlled, phase 3 trial between Oct 6, 2009, and Jan 26, 2012, at 119 centres in 29 coun

3 Between Oct 6, 2014, and April 4, 2023, 201 individuals were ran

4 Between Oct 6, 2014, and Oct 12, 2015, 229 patients were enrolle

5 Between Feb 24, 2020, and Oct 6, 2021, 268 participants were screened, and 192 wer

6 Between Nov 2, 2016, and Oct 6, 2021, 328 participants were allocated to methotre

7 From Oct 6, 2021, to March 8, 2022, 6361 randomly sampled you

8 Between Oct 6, 2022 and Aug 22, 2023, 1145 people responded to t

9 ilot intervention, implemented from Aug 8 to Oct 6, 2022, for all scheduled appointments.

10 participants recruited between July 19, and Oct 6, 2022.

11 ha3 gene promoter is activated by SCIP/Tst-1/Oct-6, a POU domain transcription factor proposed to be

12 Tst-1/SCIP/Oct-6, a POU domain transcription factor, is transiently

13 Oct-6, a POU-III domain transcription factor, is express

14 iting NF-kappaB also prevented activation of Oct-6, a transcription factor induced by axonal contact

15 They fail to downregulate Oct-6 and arrest at the premyelinating stage.

16 e in the cAMP-regulated transcription factor Oct-6 and expression of myelin basic protein.

17 otype of Schwann cells, including SCIP/tst-1/Oct-6 and Krox-20, both of which are required for the no

18 promoter in 293 cells, and YY1, Sp1, Oct-1, Oct-6, C/EBP, and c-Jun transcription factors seem to be

19 lliger oxidation (1R, 5S)-3-oxabicyclo[3.3.0]oct-6-en-2-one and (1S, 5R)-2-oxabicyclo[3.3.0]oct-6-en-

20 selective oxidation of an 8-oxabicyclo[3.2.1]oct-6-en-3-one cycloadduct by means of the Moriarty meth

21 t-6-en-2-one and (1S, 5R)-2-oxabicyclo[3.3.0]oct-6-en-3-one were detected.

22 Bicyclo[3.2.1]oct-6-en-8-ylidene (1) can assume either the conformatio

23 ridgehead nitrones, 8-oxa-6-azabicyclo[3.2.1]oct-6-ene 6-oxides, have been assembled diastereoselecti

24 m the LacZ gene seems to parallel Tst-1/SCIP/Oct-6 expression from the endogenous tst-1/scip/oct-6 ge

25 Western blot analysis was used to study Oct-6 expression in the frontal and temporal cortex in t

26 The presence of Oct-6 expression in the schizophrenic subjects but not i

27 Immunohistochemistry was used to examine Oct-6 expression in the temporal lobe in postmortem tiss

28 -6 mice, in which one copy of the tst-1/scip/oct-6 gene has been replaced with the LacZ gene.

29 -6 expression from the endogenous tst-1/scip/oct-6 gene in developing and regenerating sciatic nerves

30 /oct-6-null mice, indicating that Tst-1/SCIP/Oct-6 has a critical role in promyelinating Schwann cell

31 In schizophrenic subjects, Oct-6 immunoreactivity was found in a subset of cells in

32 Extensive Oct-6 immunoreactivity was present in the temporal lobe

33 This study evaluated the expression of Oct-6 in schizophrenia, a disorder that has been linked

34 tern blot analysis confirmed the presence of Oct-6 in the frontal and temporal cortex in schizophreni

35 Pou3f1/SCIP/Oct-6 is a POU-domain transcription factor that is an im

36 in transcription factor pou3f1 (Tst-1, SCIP, Oct-6) is required for the normal differentiation of mye

37 not in the comparison subjects suggests that Oct-6 may provide a marker for the neuropathology associ

38 a-gal) expression in heterozygous tst-1/scip/oct-6 mice, in which one copy of the tst-1/scip/oct-6 ge

39 which development is arrested in tst-1/scip/oct-6-null mice, indicating that Tst-1/SCIP/Oct-6 has a

40 In tst-1/scip/oct-6-null sciatic nerves, Schwann cells are transiently

41 f beta-gal, a surrogate marker of Tst-1/SCIP/Oct-6, peaks at the same stage of Schwann cell developme

42 Deletion of the Tst-1/Oct-6/SCIP gene produces a severe defect in peripheral m

43 The POU domain transcription factor Tst-1/Oct-6/SCIP is expressed transiently during myelination,

44 n and migration of specific neurons in Tst-1/Oct-6/SCIP mutant homozygotes is associated with a fatal

45 genes appears to be unaffected by the Tst-1/Oct-6/SCIP mutation, demonstrating that multiple, indepe

46 i (Skn-1a/i/Epoc/Oct-11) and Testes-1 (Tst-1/Oct-6/SCIP) in epidermis where proliferating basal kerat

47 Oct-6 staining was predominantly localized in the cytopl

48 the proximal rGnRH promoter containing SCIP/Oct-6/Tst-1 binding sites.

49 Activation of SCIP/Oct-6/Tst-1 expression in terminally differentiated GnRH

50 Coexpression of SCIP/Oct-6/Tst-1 in neuronal cells inhibited rat GnRH (rGnRH)

51 n-protein interactions are required for SCIP/Oct-6/Tst-1 modulation of GnRH gene expression.

52 ivity was suggested by the detection of SCIP/Oct-6/Tst-1 mRNA in a subset of GnRH neurons in the hypo

53 ion assays demonstrated the presence of SCIP/Oct-6/Tst-1 mRNA in the GnRH-producing neuronal cell lin

54 UP-TFI acts as an upstream regulator of SCIP/Oct-6/Tst-1, a transcription factor involved in axon mye

55 opment, is regulated by the POU protein SCIP/Oct-6/Tst-1.

56 ermine when Schwann cells express Tst-1/SCIP/Oct-6, we examined beta-galactosidase (beta-gal) express

57 Eyes with GA were imaged with a swept-source OCT 6 x 6 mm scan pattern.

58 -sectional retrospective study, swept-source OCT 6 x 6 mm scans on Plex Elite 9000 device were obtain

59 hyl-but-2-enyl)-oxiranyl ]-1-oxa-spiro [2.5] oct-6-yl ester (PPI-2458), in a rat model of peptidoglyc